Cite
HARVARD Citation
Smart, K. et al. (2020). PK/PD Mediated Dose Optimization of Emactuzumab, a CSF1R Inhibitor, in Patients With Advanced Solid Tumors and Diffuse‐Type Tenosynovial Giant Cell Tumor. Clinical pharmacology & therapeutics. 108 (3), pp. 616-624. [Online].